November 12, 2025Blog
Company recognized for advancing precision oncology through its physics-driven cancer prediction platform and accelerating growth
Newton, Massachusetts – November 12, 2025 – 4D Path, a company dedicated to personalizing cancer care through a novel, physics-inspired approach to predicting tumor response to therapy, today announced it has been named a winner of the Boston Business Journal’s prestigious BostInno Fire Award in the biotech category.
The BostInno Fire Awards celebrate companies driving Boston’s innovation economy—those that are raising capital, launching new products, expanding their footprint, and fueling progress across industries. 4D Path stood out for its groundbreaking approach to predicting patient-specific response to therapy directly from standard biopsy images, ushering in a new era of personalized treatment prediction in cancer care.
Over the past several years, 4D Path has continued to accelerate its mission to help every person impacted by cancer receive the best, most personalized treatment plan to beat cancer and live a longer, healthier life, achieving several major milestones:
• Clinical Validation: Completed clinical trials with Dana-Farber Cancer Institute and the Translational Breast Cancer Research Consortium, demonstrating strong predictive accuracy in standard of care treatment response for both early-stage and metastatic triple negative breast cancer and early-stage ER+/HER2- breast cancer patients.
• Strategic Partnerships: Established collaborations with leading global clinical research organizations and biopharma innovators in immunotherapy, ADCs, targeted, and endocrine therapies.
• Portfolio Growth: Developed a multi-program predictive digital biomarker R&D portfolio across breast, bladder, ovarian, and colorectal cancers in partnership with academic and biopharma research organizations
In 2025, 4D Path also welcomed leading oncologists and pathologists from Yale, Dana-Farber Cancer Institute, William N. Pennington Cancer Institute at Renown Health, Beth Israel Deaconess Medical Center, and the WHO Classification Board to its Scientific Advisory Board, reinforcing the scientific rigor behind its QPOR™ platform.
“Winning the BostInno Fire Award is a reflection of how far we’ve come, and how quickly our innovations are changing the precision oncology landscape,” said Jacopo Leonardi, CEO of 4D Path. “We’re proud to be recognized among Boston’s top innovators as we continue to make meaningful strides toward more accurate and effective treatment prediction, and improved outcomes for patients everywhere.”
About 4D Path
4D Path has created a groundbreaking platform, the patented Q-Plasia OncoReader (QPOR™), designed to directly measure and quantify cell cycle deregulation and tumor immune microenvironment dynamics to predict a patient’s response to therapy. This unprecedented view into tumor dynamics creates new pathways from clinical use to research and development applications—bringing more effective, personalized therapies to patients. 4D Path is focused on a bold vision where every person impacted by cancer is diagnosed quickly and accurately and receives the best, most personalized treatment plan to beat cancer and live a longer, healthier life.
For additional information, please visit www.4dpath.com or follow 4D Path on LinkedIn.
PR Contact
Jordan Bouclin / Jill Anderson
SVM PR & Marketing Communications
Jordan.bouclin@svmpr.com / Jill.anderson@svmpr.com
(401) 490-9700